Bcl-xL antagonist 2,98.46%
产品编号:Bellancom-12908| CAS NO:1235032-75-3| 分子式:C21H16N4O3S2| 分子量:436.51
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
Bcl-xL antagonist 2
| 产品介绍 | Bcl-xL antagonist 2 是一种有效的,选择性的,并具有口服活性的 BCL-XL 拮抗剂。IC50 和 Ki 值分别为 0.091 μM和 65 nM。Bcl-xL antagonist 2 可以促进癌细胞凋亡 (apoptosis)。Bcl-xL antagonist 2 有针对研究慢性淋巴细胞白血病 (CLL) 和非霍奇金淋巴瘤 (NHL) 的潜力。 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 生物活性 | Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-XL with an IC50 and Ki of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the apoptosis of cancer cells. Bcl-xL antagonist 2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL). | ||||||||||||||||
| 体外研究 | |||||||||||||||||
| 体内研究 |
Assessment of Pharmacokinetics (PK) profile of Bcl-xL antagonist 2 (compound 14) in rat.
西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
| 体内研究 |
Assessment of Pharmacokinetics (PK) profile of Bcl-xL antagonist 2 (compound 14) in rat.
西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
| 性状 | Solid | ||||||||||||||||
| 溶解性数据 |
In Vitro:
DMSO : 62.5 mg/mL (143.18 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
*以上所有助溶剂都可在 西域 网站选购。
| ||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
| 储存方式 |
| ||||||||||||||||
| 参考文献 |
| ||||||||||||||||

浙公网安备 33010802013016号